Quantinno Capital Management LP Has $2.55 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Quantinno Capital Management LP boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 51.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,097 shares of the life sciences company's stock after purchasing an additional 6,453 shares during the quarter. Quantinno Capital Management LP's holdings in Illumina were worth $2,552,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. NorthRock Partners LLC acquired a new position in shares of Illumina in the 4th quarter valued at $374,000. OMERS ADMINISTRATION Corp increased its stake in Illumina by 20.1% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 6,648 shares of the life sciences company's stock valued at $888,000 after acquiring an additional 1,114 shares during the period. Meridiem Capital Partners LP acquired a new position in Illumina in the fourth quarter worth about $12,712,000. Laurion Capital Management LP bought a new position in Illumina during the fourth quarter worth about $950,000. Finally, Integral Health Asset Management LLC bought a new position in Illumina during the fourth quarter worth about $5,345,000. Institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ILMN shares. Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Guggenheim reduced their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group dropped their target price on shares of Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Finally, Stephens reissued an "overweight" rating and set a $105.00 price target on shares of Illumina in a report on Tuesday, May 20th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and an average target price of $128.15.

Illumina Trading Down 0.2%

Illumina stock traded down $0.17 during midday trading on Monday, hitting $80.37. 1,536,714 shares of the stock were exchanged, compared to its average volume of 2,326,484. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $12.72 billion, a PE ratio of -10.46, a P/E/G ratio of 1.60 and a beta of 1.35. The company has a fifty day simple moving average of $78.14 and a two-hundred day simple moving average of $108.39.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. The business's quarterly revenue was down 1.4% compared to the same quarter last year. During the same period last year, the firm posted $0.98 earnings per share. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity

In related news, CFO Ankur Dhingra acquired 6,100 shares of the business's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average cost of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.60% of the stock is currently owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.